World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
66
Citations
18261
World Ranking
2737
National Ranking
1305

Daniel J. Powell publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Daniel J. Powell sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 185 publications — 29th percentile

29% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Daniel J. Powell D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Daniel J. Powell sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 66 D-Index — 45th percentile

45% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Daniel J. Powell is affiliated with the University of Pennsylvania in the United States. Their research primarily spans the fields of Medicine and Immunology and Microbiology, with a significant focus on Immunology and Oncology as key subfields. Molecular Biology, Reproductive Medicine, and Radiology, Nuclear Medicine and Imaging also feature among their research interests.

Their main research topics include:

  • CAR-T cell therapy research
  • Immune Cell Function and Interaction
  • Immunotherapy and Immune Responses
  • Cancer Immunotherapy and Biomarkers
  • Ovarian cancer diagnosis and treatment
  • Immune cells in cancer
  • Viral Infectious Diseases and Gene Expression in Insects

Powell has contributed extensively to the scientific literature, with notable recent papers including:

  • Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study, 2020, Journal of Clinical Oncology
  • CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape, 2020, Frontiers in Immunology
  • CAR-T cell-mediated depletion of immunosuppressive tumor-associated macrophages promotes endogenous antitumor immunity and augments adoptive immunotherapy, 2021, Nature Communications
  • Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation, 2021, Cancer Cell
  • NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma, 2021, Blood Cancer Journal

Their frequent co-authors include:

  • Sarah B. Gitto
  • Mathilde Poussin
  • Monika A. Eiva
  • Alba Rodríguez-García
  • Fiona Simpkins

Powell's work is often published in several leading venues, notably:

  • Cancer Research
  • Regular and Young Investigator Award Abstracts
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Cancer Cell
  • Nature Cancer

Best Publications

  • Adoptive immunotherapy for cancer: building on success.

    Luca Gattinoni;Daniel J. Powell;Steven A. Rosenberg;Nicholas P. Restifo

  • Rethinking ovarian cancer II: Reducing mortality from high-grade serous ovarian cancer

    David D. Bowtell;David D. Bowtell;Steffen Böhm;Ahmed A. Ahmed;Paul Joseph Aspuria

  • Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors

    Denarda Dangaj;Marine Bruand;Alizée J. Grimm;Catherine Ronet

  • Cutting Edge: Persistence of Transferred Lymphocyte Clonotypes Correlates with Cancer Regression in Patients Receiving Cell Transfer Therapy

    Paul F. Robbins;Mark E. Dudley;John Wunderlich;Mona El-Gamil

  • Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T Cells Expressing a Mesothelin - Specific Chimeric Antibody Receptor

    Edmund K. Moon;Carmine Carpenito;Jing Sun;Liang-Chuan S. Wang

  • Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer

    Janos L. Tanyi;Sara Bobisse;Eran Ophir;Sandra Tuyaerts

  • Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy

    Daniel J. Powell;Mark E. Dudley;Paul F. Robbins;Steven A. Rosenberg

  • CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo.

    De Gang Song;De Gang Song;Qunrui Ye;Mathilde Poussin;Gretchen M. Harms

  • Gene Transfer of Tumor-Reactive TCR Confers Both High Avidity and Tumor Reactivity to Nonreactive Peripheral Blood Mononuclear Cells and Tumor-Infiltrating Lymphocytes

    Laura A. Johnson;Bianca Heemskerk;Daniel J. Powell;Cyrille J. Cohen

  • Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo.

    Evripidis Lanitis;Mathilde Poussin;Alex W. Klattenhoff;Degang Song

  • In Vivo Persistence, Tumor Localization, and Antitumor Activity of CAR-Engineered T Cells Is Enhanced by Costimulatory Signaling through CD137 (4-1BB)

    De Gang Song;Qunrui Ye;Carmine Carpenito;Mathilde Poussin

  • Tumor infiltrating lymphocytes in ovarian cancer

    Phillip P Santoiemma;Daniel J Powell

  • CD25 Blockade Depletes and Selectively Reprograms Regulatory T Cells in Concert with Immunotherapy in Cancer Patients

    Andrew J. Rech;Rosemarie Mick;Sunil Martin;Adri Recio

  • A Universal Strategy for Adoptive Immunotherapy of Cancer through Use of a Novel T-cell Antigen Receptor

    Katarzyna Urbanska;Evripidis Lanitis;Mathilde Poussin;Rachel C. Lynn

  • CD137 Accurately Identifies and Enriches for Naturally Occurring Tumor-Reactive T Cells in Tumor

    Qunrui Ye;De-Gang Song;Mathilde Poussin;Tori Yamamoto

  • Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study

    Dmitriy Zamarin;Robert A. Burger;Michael W. Sill;Daniel J. Powell

  • The RET/PTC3 oncogene : Metastatic solid-type papillary carcinomas in murine thyroids

    Daniel J. Powell;John Russell;Ken-ichi Nibu;Guoqi Li

  • CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape.

    Alba Rodriguez-Garcia;Asis Palazon;Estela Noguera-Ortega;Daniel J. Powell

  • CAR-T cell-mediated depletion of immunosuppressive tumor-associated macrophages promotes endogenous antitumor immunity and augments adoptive immunotherapy.

    Alba Rodriguez-Garcia;Rachel C. Lynn;Mathilde Poussin;Monika A. Eiva

  • A Dendritic Cell Vaccine Pulsed with Autologous Hypochlorous Acid-Oxidized Ovarian Cancer Lysate Primes Effective Broad Antitumor Immunity: From Bench to Bedside

    Cheryl Lai-Lai Chiang;Lana E. Kandalaft;Janos Tanyi;Andrea R. Hagemann

  • Redirected Antitumor Activity of Primary Human Lymphocytes Transduced With a Fully Human Anti-mesothelin Chimeric Receptor

    Evripidis Lanitis;Mathilde Poussin;Ian S Hagemann;George Coukos

Frequent Co-Authors

George Coukos
George Coukos Cornell University
Lana E. Kandalaft
Lana E. Kandalaft Ludwig Cancer Research
Carl H. June
Carl H. June University of Pennsylvania
Steven A. Rosenberg
Steven A. Rosenberg National Institutes of Health
Bruce L. Levine
Bruce L. Levine University of Pennsylvania
Rosemarie Mick
Rosemarie Mick University of Pennsylvania
Michael C. Milone
Michael C. Milone University of Pennsylvania
Nicholas P. Restifo
Nicholas P. Restifo National Institutes of Health
Mark E. Dudley
Mark E. Dudley Novartis (Switzerland)
Philip D. Greenberg
Philip D. Greenberg Fred Hutchinson Cancer Research Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in Immunology, various healthcare-related online degree programs offer complementary pathways. For example, accelerated bsn programs for non nurses provide an efficient route for those shifting from other fields into nursing. These programs emphasize foundational medical knowledge with accelerated timelines, making them an attractive option for career changers.

Similarly, aspiring nurses may explore easy admission lpn programs that offer accessible entry points into the healthcare sector. These programs focus on practical nursing skills and prepare graduates to support patient care effectively, aligning well with foundational immunology knowledge.

For those aiming to advance their qualifications, the easiest fnp program options simplify the process of becoming a Family Nurse Practitioner. This advanced role integrates immunological understanding for managing patient health across diverse populations.

Mental health specialties are also relevant, as immunology increasingly intersects with psychiatric care. Prospective students can consider the best pmhnp programs with best clinical placement rates to gain clinical experience in psychiatric mental health nursing while leveraging immunology insights in practice.

Exploring these related degrees can enrich an immunology student’s career prospects, blending foundational science with practical healthcare skills.

accelerated bsn programs for non nurses
easy admission lpn programs
easiest fnp program
best pmhnp programs

Best Scientists Citing Daniel J. Powell

Trending Scientists

Recently Published Articles